Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus POSACONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus POSACONAZOLE.
GYNE-LOTRIMIN 3 vs POSACONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
300 mg orally twice daily on day 1, then 300 mg once daily thereafter. Extended-release tablets: 300 mg orally twice daily on day 1, then 300 mg once daily. Intravenous: 300 mg IV twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
Clinical Note
moderatePosaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast."
Clinical Note
moderatePosaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic acid."
Clinical Note
moderatePosaconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide."
Clinical Note
moderateTerminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Terminal elimination half-life: 35 hours (range 25–50 hours), allowing once-daily dosing after steady state; prolonged in hepatic impairment.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Fecal (77% as unchanged drug) and renal (14% as glucuronide conjugates); <1% excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal
Posaconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronic acid."